Poultry
xClose

Loading ...
Swine
xClose

Loading ...
Dairy & Ruminant
xClose

Loading ...
Aquaculture
xClose

Loading ...
Feed
xClose

Loading ...
Animal Health
xClose

Loading ...
Industry Happenings


September 13, 2018

 

DSM, Novozymes launch world's first 'gut-cleaning' enzyme

 


 

An innovation in broiler nutrition, Balancius™ is the first and only microbial muramidase (or lysozyme) that works in the intestine to improve feed efficiency and increase sustainable product yield.


The unique mode of action of the naturally-occuring muramidase breaks-down peptidoglycans (PGNs) in bacterial cell debris, thus unlocking the potential in gastrointestinal functionality.


Scientific data demonstrate the addition of Balancius™ to the diet of broiler chickens consistently improves feed conversion ratio by 3%, demonstrating a significant improvement in digestibility and feed efficiency.


The launch of Balancius™ is the latest innovation from the Alliance of DSM with Novozymes.


The announcement is supported by data from 40 international studies that showed the addition of Balancius to poultry feed significantly improved the feed conversion ratio and weight gain. Ongoing trials are currently addressing the potential for the extension of Balancius into other species.


"These results demonstrate that optimising gastrointestinal functionality through the unique action of Balancius significantly improves feed efficiency and encourages weight gain of broiler chickens. These results have the potential to dramatically improve capacity for sustainable poultry production and translate to significant savings for individual production managers," explains Eduardo Alberto, DSM Vice President Animal Nutrition & Health - North America.


"Together, DSM and Novozymes have developed a solution that contributes to the growth and welfare of animals by removing bacterial cell debris from the chicken's gut. No other technology works like this," says Susanne Palsten Buchardt, Vice President at Novozymes for Animal Health & Nutrition Commercial. "It's a game-changing innovation based on our 20-year Alliance with DSM."


To date, Balancius is registered in LATAM (Brazil, Argentina, Chile, Colombia, Costa Rica, Mexico), in the US and in APAC (Bangladesh, Pakistan and India). EMEA will follow soon (mid-2019), after a positive opinion published by EFSA EU in June this year.

Share this article on FacebookShare this article on TwitterPrint this articleForward this article
Previous
My eFeedLink last read